N2U0.F Adlai Nortye Ltd.
- Market cap
- EUR 773M
- P/E
- -
- P/B
- 4.04x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is N2U0.F undervalued?
Graham numberThe Graham number of Adlai Nortye Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Adlai Nortye Ltd. fundamental analysis
No fundamental analysis for Adlai Nortye Ltd. yet.
Adlai Nortye Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Adlai Nortye Ltd.
Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors. Its immunotherapy programs include AN8025, a…
Full company profileAdlai Nortye Ltd. financial statements
Adlai Nortye Ltd. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 45.7M | 0.00 | 0.00 | 0.00 | 5.00M |
| Operating Income | -8.65M | -67.3M | -72.6M | -52.9M | -35.7M |
| EBITDA | - | -56.3M | -106M | -48.1M | -32.6M |
| Net Income | -56.7M | -58.8M | -109M | -51.9M | -35.5M |
| EPS | -0.51 | -0.53 | -0.99 | -0.47 | -0.30 |
| Balance Sheet | |||||
| Total Assets | 132M | 72.6M | 130M | 71.3M | 34.4M |
| Total Liabilities | 317M | 314M | 55.1M | 45.8M | 42.8M |
| Shareholders' Equity | -185M | -241M | 75.0M | 25.5M | -8.32M |
| Cash & Short-term Investments | 64.1M | 42.8M | 91.5M | 60.9M | 8.06M |
| Cash Flow | |||||
| Operating Cash Flow | -3.03M | -43.2M | -56.7M | -51.8M | -33.5M |
| Capital Expenditure | 1.12M | 1.27M | 200K | 170K | 187K |
| Free Cash Flow | -4.15M | -44.5M | -56.9M | -52.0M | -33.6M |
| Ratios | |||||
| ROE | - | - | -145.5% | -203.5% | - |
| ROA | -43.0% | -81.0% | -83.9% | -72.8% | -103.2% |
| Net Profit Margin | -124.0% | - | - | - | -710.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Adlai Nortye Ltd. dividends
Adlai Nortye Ltd. has not paid dividends in the last 5 fiscal years.
Who owns Adlai Nortye Ltd.
- Insiders 0.94%
- Institutions 41.56%
- Public & others 57.50%
- Shares outstanding 58.7M
- Free float 49.6M
Adlai Nortye Ltd. company profile
- Company name
- Adlai Nortye Ltd.
- Ticker
- N2U0.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 109
- Fiscal year end
- December
- Address
- 77 Robinson Road, Singapore, Singapore, 068896
- Phone
- 848 230 7430
- Website
- adlainortye.com
About Adlai Nortye Ltd.
Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors. Its immunotherapy programs include AN8025, a tri-functional fusion protein (aPD-L1 x CD86 variant x LAG3 variant) that modulates T-cells and antigen-presenting cells; AN0025, a small molecule EP4 antagonist; and AN4005, an oral small-molecule PD-L1 inhibitor. The company supports its pipeline through an immuno-oncology research and development platform with operations in the United States and China. Adlai Nortye Group Ltd. was formerly known as Adlai Nortye Ltd. and changed its name to Adlai Nortye Group Ltd. in July, 2026. Adlai Nortye Group Ltd. was founded in 2004 and is based in Singapore.
Adlai Nortye Ltd. management
6- Mr. Yang Lu EMBACo- Founder, CEO & Chairman · born 1979
- Dr. Ngai Chiu Tse M.D., Ph.D.President & Head of Research & Development · born 1967
- Dr. Xiaofeng Ye Ph.D.Chief Financial Officer · born 1979
- Dr. Zhiyong Yu Ph.D.Vice President of Operations
- Mr. Christopher Liu Pharm.D.Head of Investor Relations & Public Relations
- Dr. Nanhai He Ph.D.Head of Discovery